DK1451177T3 - Substituerede 2-pyrrolidin-2-yl-1H-indol-derivater til behandling af migræne - Google Patents
Substituerede 2-pyrrolidin-2-yl-1H-indol-derivater til behandling af migræneInfo
- Publication number
- DK1451177T3 DK1451177T3 DK02798318T DK02798318T DK1451177T3 DK 1451177 T3 DK1451177 T3 DK 1451177T3 DK 02798318 T DK02798318 T DK 02798318T DK 02798318 T DK02798318 T DK 02798318T DK 1451177 T3 DK1451177 T3 DK 1451177T3
- Authority
- DK
- Denmark
- Prior art keywords
- migraine
- pyrrolidin
- substituted
- treatment
- indole derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10159922A DE10159922A1 (de) | 2001-12-06 | 2001-12-06 | Substituierte 2-Pyrrolidin-2-yl-1H-indol-Derivate |
PCT/EP2002/013613 WO2003048156A1 (de) | 2001-12-06 | 2002-12-02 | Substituierte 2-pyrrolidin-2-yl-1h-indol-derivative für die behandlung von migräne |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1451177T3 true DK1451177T3 (da) | 2007-07-02 |
Family
ID=7708242
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK02798318T DK1451177T3 (da) | 2001-12-06 | 2002-12-02 | Substituerede 2-pyrrolidin-2-yl-1H-indol-derivater til behandling af migræne |
Country Status (18)
Country | Link |
---|---|
US (1) | US7271192B2 (el) |
EP (1) | EP1451177B1 (el) |
JP (1) | JP4663982B2 (el) |
AR (1) | AR037707A1 (el) |
AT (1) | ATE357441T1 (el) |
AU (1) | AU2002363859B2 (el) |
CA (1) | CA2469346C (el) |
CY (1) | CY1106576T1 (el) |
DE (2) | DE10159922A1 (el) |
DK (1) | DK1451177T3 (el) |
ES (1) | ES2284973T3 (el) |
HU (1) | HUP0402283A3 (el) |
MX (1) | MXPA04005139A (el) |
PE (1) | PE20030748A1 (el) |
PL (1) | PL371270A1 (el) |
PT (1) | PT1451177E (el) |
SI (1) | SI1451177T1 (el) |
WO (1) | WO2003048156A1 (el) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7851478B2 (en) | 2005-06-07 | 2010-12-14 | Kyowa Hakko Kirin Co., Ltd. | Agent for preventing and/or treating movement disorder |
AR079528A1 (es) * | 2009-12-18 | 2012-02-01 | Idenix Pharmaceuticals Inc | Inhibidores de arileno o heteroarileno 5,5-fusionado del virus de la hepatitis c |
US10092574B2 (en) | 2012-09-26 | 2018-10-09 | Valorisation-Recherche, Limited Partnership | Inhibitors of polynucleotide repeat-associated RNA foci and uses thereof |
CN112010841A (zh) * | 2020-08-20 | 2020-12-01 | 上海体育学院 | 一种基于吲哚骨架的吡咯烷衍生物及其制备方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3506683A (en) * | 1963-10-07 | 1970-04-14 | Upjohn Co | 3-(2-pyrrolidinylidene)-3h-indoles |
KR0184911B1 (ko) * | 1991-11-25 | 1999-05-01 | 알렌 제이. 스피겔 | 인돌유도체 |
GB9201038D0 (en) * | 1992-01-16 | 1992-03-11 | Glaxo Group Ltd | Chemical compounds |
AU686654B2 (en) * | 1993-08-31 | 1998-02-12 | Pfizer Inc. | 5-arylindole derivatives |
GB9523999D0 (en) * | 1995-11-23 | 1996-01-24 | Lilly Co Eli | Indolyl neuropeptide y receptor antagonists |
HN1998000118A (es) * | 1997-08-27 | 1999-02-09 | Pfizer Prod Inc | 2 - aminopiridinas que contienen sustituyentes de anillos condensados. |
CA2425185A1 (en) * | 2000-10-06 | 2002-04-11 | Stephane De Lombaert | Benzimidazole and indole derivatives as crf receptor modulators |
-
2001
- 2001-12-06 DE DE10159922A patent/DE10159922A1/de not_active Withdrawn
-
2002
- 2002-12-02 AT AT02798318T patent/ATE357441T1/de active
- 2002-12-02 WO PCT/EP2002/013613 patent/WO2003048156A1/de active IP Right Grant
- 2002-12-02 JP JP2003549346A patent/JP4663982B2/ja not_active Expired - Fee Related
- 2002-12-02 EP EP02798318A patent/EP1451177B1/de not_active Expired - Lifetime
- 2002-12-02 AU AU2002363859A patent/AU2002363859B2/en not_active Ceased
- 2002-12-02 DE DE50209798T patent/DE50209798D1/de not_active Expired - Lifetime
- 2002-12-02 DK DK02798318T patent/DK1451177T3/da active
- 2002-12-02 PL PL02371270A patent/PL371270A1/xx not_active IP Right Cessation
- 2002-12-02 MX MXPA04005139A patent/MXPA04005139A/es active IP Right Grant
- 2002-12-02 SI SI200230538T patent/SI1451177T1/sl unknown
- 2002-12-02 PT PT02798318T patent/PT1451177E/pt unknown
- 2002-12-02 CA CA2469346A patent/CA2469346C/en not_active Expired - Fee Related
- 2002-12-02 HU HU0402283A patent/HUP0402283A3/hu unknown
- 2002-12-02 ES ES02798318T patent/ES2284973T3/es not_active Expired - Lifetime
- 2002-12-04 PE PE2002001168A patent/PE20030748A1/es not_active Application Discontinuation
- 2002-12-05 AR ARP020104713A patent/AR037707A1/es unknown
-
2004
- 2004-06-07 US US10/861,426 patent/US7271192B2/en not_active Expired - Fee Related
-
2007
- 2007-05-10 CY CY20071100631T patent/CY1106576T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
PT1451177E (pt) | 2007-04-30 |
AR037707A1 (es) | 2004-12-01 |
PE20030748A1 (es) | 2003-09-05 |
ES2284973T3 (es) | 2007-11-16 |
DE10159922A1 (de) | 2003-06-26 |
AU2002363859A1 (en) | 2003-06-17 |
PL371270A1 (en) | 2005-06-13 |
HUP0402283A3 (en) | 2009-07-28 |
CY1106576T1 (el) | 2012-01-25 |
CA2469346C (en) | 2010-10-19 |
MXPA04005139A (es) | 2004-08-11 |
EP1451177B1 (de) | 2007-03-21 |
EP1451177A1 (de) | 2004-09-01 |
SI1451177T1 (sl) | 2007-08-31 |
HUP0402283A2 (hu) | 2005-02-28 |
WO2003048156A1 (de) | 2003-06-12 |
AU2002363859B2 (en) | 2008-09-18 |
JP4663982B2 (ja) | 2011-04-06 |
ATE357441T1 (de) | 2007-04-15 |
US20050014815A1 (en) | 2005-01-20 |
JP2005511694A (ja) | 2005-04-28 |
US7271192B2 (en) | 2007-09-18 |
DE50209798D1 (de) | 2007-05-03 |
CA2469346A1 (en) | 2003-06-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1762567T3 (da) | Pyrazolderivater til behandling af HIV | |
DK1144395T3 (da) | 2-amino-benzoxazinon-derivater til behandling af fedme | |
DK1343773T3 (da) | Thiazolderivater til behandling af PPAR-beslægtede forstyrrelser | |
DK1803718T3 (da) | 4-Tetrazolyl-4-phenylpiperidin-derivater til behandling af smerter | |
DK1147083T3 (da) | Arylpiperazinyl-cyclohexylindolderivater til behandling af depression | |
DK1438306T3 (da) | Derivater af UK-2A | |
IS7099A (is) | Efnasambönd til að meðhöndla bólgutruflanir | |
DK1259512T3 (da) | Pteridinforbindelser til behandling af psoreasis | |
DK1292594T3 (da) | Quinazolinderivater til behandling af tumorer | |
NO20042680L (no) | Fremgangsmater for fremstilling av O-demetylvenflaxine | |
DK1474416T3 (da) | Dihydrobenzodiazepin-2-on-derivater til behandlingen af neurologiske lidelser | |
DK1448205T3 (da) | Kombinationer til behandling af immunoinflammatoriske sygdomme | |
DK1143977T3 (da) | 2-oxy-benzoxazinonderivater til behandling af obesitas | |
DK1499730T3 (da) | Immunokonjugater til behandling af tumorer | |
DK1392318T3 (da) | 15-keto-prostaglandiner til behandling af lægemiddelinduceret forstoppelse | |
DK1380121T3 (da) | Fremgangsmåde til fremstilling af oxazolidinoner | |
IS6917A (is) | Epóþílon afleiður til meðhöndlunar erfiðra æxla | |
NO20040253L (no) | Fremgangsmater for behandling av leverfibroser | |
DK1231920T3 (da) | Anvendelse af epinastin til behandling af allergisk rhinitis/conjunctivitis | |
DK1206436T3 (da) | Retinoider til behandling af emfysem | |
DK1667967T3 (da) | Fremgangsmåde til fremstilling af 2-oxo-1-pyrrolidin-derivater | |
DK1456229T3 (da) | Fremgangsmåe til fremstilling af echinocandin-derivater | |
DK1268482T3 (da) | Pyranoindoler til behandling af glaukom | |
DK1468996T3 (da) | Indolderivater til behandling af CNS-sygdomme | |
DK1511724T3 (da) | Fremgangsmåde til fremstilling af thioalkylaminderivater |